

# BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI – 400 001.  
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22615327

8<sup>th</sup> February, 2020

To,  
Department of Corporate Service  
Corporate Relation Department  
**Bombay Stock Exchange Ltd.,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

**BSE Script Code: 524516**

**Sub.: Outcome of Board Meeting**

Dear Sir/Madam,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following;

1. Unaudited Financial Results of the Company for the Quarter and Nine Months ended 31st December, 2019 duly approved and taken on record by the Board of Directors of the Company.
2. Auditors' Limited Review Report on the above Unaudited Financial Results issued by the Statutory Auditors of the Company and taken on record by the Board of Directors of the Company.

The Board Meeting was concluded at 3:30 p.m.

You are hereby requested to take the same on records.

Thanking You

Yours Faithfully  
For **Bacil Pharma Ltd.**



Director



Enclosure: As above



**BACIL PHARMA LIMITED**

CIN:L24200MH1987PLC043427

**UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2019**

(Amount in Lacs)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2019 (Unaudited)	30.09.2019 (Unaudited)	31.12.2018 (Unaudited)	31.12.2019 (Unaudited)	31.12.2018 (Unaudited)	31.03.2019 (Audited)
1	Revenue from operations	-	-	-	-	-	-
	Other income	1.97	8.86	1.64	12.45	4.70	9.41
	<b>Total revenue</b>	<b>1.97</b>	<b>8.86</b>	<b>1.64</b>	<b>12.45</b>	<b>4.70</b>	<b>9.41</b>
2	<b>Expenses</b>						
	Employee benefits expense	2.71	2.51	2.57	7.13	6.65	7.87
	Depreciation and amortization expense	0.21	0.21	0.21	0.62	0.65	0.91
	Other expenses	23.89	5.13	7.75	34.00	26.55	34.98
	<b>Total expenses</b>	<b>26.81</b>	<b>7.85</b>	<b>10.54</b>	<b>41.74</b>	<b>33.85</b>	<b>43.76</b>
3	<b>Profit/(Loss) from exceptional item before tax</b>	<b>(24.84)</b>	<b>1.01</b>	<b>(8.90)</b>	<b>(29.30)</b>	<b>(29.15)</b>	<b>(34.35)</b>
	Exceptional Item	-	-	-	-	-	-
4	<b>Profit / (Loss) from ordinary activities before tax</b>	<b>(24.84)</b>	<b>1.01</b>	<b>(8.90)</b>	<b>(29.30)</b>	<b>(29.15)</b>	<b>(34.35)</b>
5	<b>Tax expense:</b>						
	(1) Current tax	-	-	-	-	-	-
	(2) Earlier year's Tax	-	-	-	-	-	-
	(3) Deferred tax	(0.03)	0.02	-	(0.01)	-	(0.11)
	<b>Total tax expense</b>	<b>(0.03)</b>	<b>0.02</b>	<b>-</b>	<b>(0.01)</b>	<b>-</b>	<b>(0.11)</b>
6	<b>Profit/(Loss) from ordinary activities after tax</b>	<b>(24.81)</b>	<b>0.99</b>	<b>(8.90)</b>	<b>(29.29)</b>	<b>(29.15)</b>	<b>(34.24)</b>
7	<b>Other Comprehensive Income (OCI)</b>						
	<u>Item that will not be reclassified to profit or loss</u>						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	14.10	(9.82)	13.58	(8.51)	(8.47)	(0.26)
	Income tax relating to these items	(3.67)	2.55	(3.36)	2.21	3.92	1.92
	<b>Total Other Comprehensive Income (OCI)</b>	<b>10.43</b>	<b>(7.27)</b>	<b>10.21</b>	<b>(6.29)</b>	<b>(4.55)</b>	<b>1.66</b>
	<b>Profit/(Loss) for the Period</b>	<b>(14.38)</b>	<b>(6.28)</b>	<b>1.31</b>	<b>(35.58)</b>	<b>(33.70)</b>	<b>(32.58)</b>
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	589.00	589.00	589.00	589.00	589.00	589.00
8	<b>Earning Per Share ( EPS ) (Not annualised)</b>						
	(1) Basic	(0.42)	0.02	(0.15)	(0.50)	(0.49)	(0.58)
	(2) Diluted	(0.42)	0.02	(0.15)	(0.50)	(0.49)	(0.58)

**Notes:**

- The above Unaudited result have been reviewed by the Audit Committee and approved by the Board of Director at its meeting held on 08th February 2019
- The statutory Auditors of the company have carried out the limited review.
- The Company has single business segment ,therefore, in the context of Ind As 108, disclosure of segement information is not applicable.
- Previous quarter figures have been regrouped /reclassified wherever necessary, to make them comparable.

For BACIL PHARMA LIMITED

Prakash Shah  
Director  
DIN: 01136800  
Place: Mumbai  
Dated: 08/02/2020







# Laxmikant Kabra & Co.

## Chartered Accountants

### INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

To,  
The Board of Directors,  
**M/s. BACIL PHARMA LIMITED**  
Mumbai

1. We have reviewed the accompanying statement of unaudited financial results ("Statement") of **M/s. BACIL PHARMA LIMITED** (the 'Company') for the quarter and nine months ended 31<sup>st</sup> December, 2019 (the "statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the regulation'), as amended, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. These financial statements are the responsibility of the Company's management and have been approved by the Board of Directors of the Company, and have been prepared in accordance with recognition and measurement principles laid down in India. Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 and relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Laxmikant Kabra & Co.  
Chartered Accountants  
Firm Reg. No.: 117183W

*L.K. Kabra*

CA. Laxmikant Kabra  
(Partner)  
Membership No.: 101839



Place: Thane,  
Date: 08<sup>th</sup> February, 2019

UDIN: 20101839AAAAAX9148